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Abstract
SMC1 and SMC3 form a high-affinity heterodimer, which provides an open backbone of the cohesin ring, to be closed by a
kleisin protein. RNAi mediated knock-down of either one heterodimer partner, SMC1 or SMC3, is expected to cause very
similar if not identical phenotypes. However, we observed highly distinct, protein-specific phenotypes. Upon knock-down of
human SMC1, much of SMC3 remains stable, accumulates in the cytoplasm and does not associate with other cohesin
proteins. Most of the excess nuclear SMC3 is highly mobile and not or only weakly chromosome-associated. In contrast,
human SMC3 knock-down rendered SMC1 instable without cytoplasmic accumulation. As observed by differential protein
extraction and in FRAP experiments the remaining SMC1 or SMC3 proteins in the respective SMC1 or SMC3 knock-down
experiments constituted a cohesin pool, which is associated with chromatin with highest affinity, likely the least
expendable. Expression of bovine EGFP-SMC1 or mouse EGFP-SMC3 in human cells under conditions of human SMC1 or
SMC3 knock-down rescued the respective phenotypes, but in untreated cells over-expressed exogenous SMC proteins mis-
localized. Paucity of either one of the SMC proteins causes RAD21 degradation. These results argue for great caution in
interpreting SMC1 and SMC3 RNAi or over-expression experiments. Under challenged conditions these two proteins
unexpectedly behave differently, which may have biological consequences for regulation of cohesin-associated functions
and for human cohesin pathologies.
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Introduction
The highly conserved nuclear protein complex cohesin is
required for sister chromatid cohesion, and is involved in DNA
repair and regulation of gene expression (for reviews see
[1,2,3,4,5,6,7,8]). Cohesin is composed of two Structural Mainte-
nance of Chromosomes proteins, SMC1 and SMC3, and a kleisin
protein like RAD21. This tripartite complex associates with other
proteins, including a HEAT repeat protein such as SA1 or SA2.
SMC1 and SMC3 carry a globular ATPase head domain, formed
by the C- and N-termini of one SMC protein, which folds back
onto itself. The N- and C-termini are linked by an extended
coiled-coil region, which is interrupted by a central hinge domain
through which SMC1 and SMC3 heterodimerize. The cohesin
ring is closed by the kleisin, which binds with its N- and C-
terminus to the head domains of SMC3 and SMC1, respectively.
Upon dimerization the hinge domains form a characteristic
doughnut-like structure with two interaction surfaces separated by
a central hole [9,10]. Hinge domains contribute to formation of a
V-shaped SMC heterodimer [10,11,12], and may be a target of
regulatory factors [13,14]. Hinge-mediated heterodimerization of
SMC1 and SMC3 appears to be very stable, for isolated hinge
dimers resist high salt and considerable detergent such as 0.01%
SDS [15]. Yet, hinge-hinge interactions are dynamic as the dimers
may open and form an entry gate for DNA [4,9,16,17]. SMC3
acetylation is thought to induce conformational changes of the
dimeric hinge structure during S phase and to allow dimer
opening and loading of DNA through a positively charged channel
within the ‘‘doughnut’’ [18].
In cells, SMC1 and SMC3 are believed to always exist as
heterodimers in a one-to-one stoichiometry. Similarly, most
prokaryotes contain only a single smc gene and its product forms
homodimers [10,19,20,21,22]. The head domain of eukaryotic
SMC1 also homodimerizes, speculated to reflect an evolutionary
relict [23]. This association is less stable than hinge-mediated
heterodimerization and it remains unclear, whether this interac-
tion would bring two SMC proteins of the same kind together in
vivo [24]. SMC1, SMC3 and RAD21 also interact each with itself.
Dimer formation in eukaryotes depends on the presence of two
different hinge regions, i.e. one each from SMC1 and SMC3. One
intact hinge interaction interface is sufficient for heterodimeriza-
tion, since replacement of three conserved glycine residues by
alanine in either the SMC1 or the SMC3 hinge does not abolish in
vitro hinge dimer formation, but mutating both hinge domains does
[15]. At least in yeast specific mutations of either one of the hinge
dimer interaction surfaces are lethal [24]. Mutated hinge domains
still dimerize but in an altered manner with reduced stability. The
residence time of such mutant cohesin complexes, which still form
in vivo, on chromosomes was reduced [24]. Isolated dimeric hinge
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Figure 1. Transient down-regulation of endogenous human SMC1 in HeLa cells using specific esiRNA or siRNA impairs the nuclear
localization of SMC3. (A) RIPA total cell extracts were prepared 72 h after treatment with three different concentrations of esiSMC1 and examined
by IB using anti-SMC1 antibody. Mock transfected cells were used as negative control. The membrane was reprobed with anti-SMC3 antibody to
confirm the specificity of esiSMC1 and equal loading. The percentages of SMC1 protein levels, normalized to SMC3 protein levels with respect to
mock control set at 100%, are indicated. (B) Kinetics of recovery of SMC1 expression after treatment of cells with 750 ng/mL of esiSMC1 was analyzed
by IB as described in A. (C) Quantification of SMC1 and SMC3 in RIPA total extracts of cells treated with 750 ng/mL of esiRNA and collected 72 h post
transfection. Average of six independent experiments is shown. (D) IF microscopic analysis of SMC1 knockdown 72 h post esiRNA transfection by
anti-SMC1 staining in red and DAPI in blue. Specific esiRNA against EGFP (esiEGFP) was used as a control. (E) IF microscopic analyses of esiSMC1- or
esiEGFP-treated cells (72 h) using anti-SMC3 (red) and DAPI (blue). (F) Cytoplasmic and nuclear extracts from esiSMC1 or control treated cells were
analyzed by IB using anti-SMC3. The membrane was reprobed with anti-SMC1. Anti-ß tubulin and Topo II antibodies were used to determine the
purity of nuclear and cytoplasm extracts. (G) Quantification of results from four independent experiments that were performed as described in F. (H)
Time course of SMC3 localization upon treatment of cells with siSMC1 (#1) as visualized by IF microscopy using anti-SMC3 (in red) and DAPI (in blue).
doi:10.1371/journal.pone.0065149.g001
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domains bind DNA in vitro [15,25]. In hinge domain mutants,
which reflect mutations seen in Cornelia de Lange Syndrome
(CdLS) patients, DNA binding is increased and the cells became
hypersensitive to irradiation [26].
In vertebrates a fraction of cohesin is bound to chromosomes at
all phases of the cell cycle except between anaphase onset and
telophase. Loading of cohesin in telophase requires several
proteins including SCC2- and SCC4-type proteins. Cohesion is
regulated by cohesion-promoting factors sororin and ESCO1/
ESCO2 and cohesion-weakening factors WAPL, PDS5 and a
histone deacetylase (reviewed in: [4,8,27]. The histone deacetylase
was recently identified as HDCA8 [28]. The dissociation of
cohesin from chromosomes involves two pathways. A large
fraction, estimated at least 90%, of cohesin is removed from the
chromosomes arms in prophase and prometaphase, triggerd by
PLK1 mediated phosphorylation of SA2. WAPL and sororin also
regulate the prophase removal pathway. Some cohesin remains
associated with centromeres and on chromosome arms and is
removed by separase cleavage of RAD21 at the meta-anaphase
transition. Reassociation of cohesin, probably cohesin released
during prophase, to chromosomes occurs already during telo-
phase. This pool of reversibly bound cohesin, which has a mean
residence time of about 25 min on chromatin, has likely important
functions regulating transcription and the chromatin structure
throughout interphase [2,3,29]. During S/G2 phase a second
population of cohesin binds much more stably to chromatin.
Soluble cohesin proteins not associated with chromatin probably
also exist in association with each other [30] and such soluble
cohesin may constitute a cohesin reservoire.
Several human pathologies are associated with failures in the
‘‘cohesin system’’. These pathologies include the above mentioned
CdLS, which features mutations in cohesin proteins SMC1 or
SMC3, or in cohesin-associated factors such as the loading factor
SCC2 (NIPBL) (reviewed in [31,32,33]) or the histone deacetylase
HDAC8 [28]. Other cohesin-related human diseases include
human cancer [34].
It is generally assumed that the SMC1/SMC3 heterodimer acts
as a functional unit, and that elimination or large disruption of
either of the two SMC proteins would cause the same or very
similar phenotypes. While this may be true for the essential
function of cohesin in sister chromatid cohesion it is not clear,
which fate the partner SMC protein experiences if one of the SMC
proteins is reduced. To perform their known biological functions,
SMC1 and SMC3 likely need to be balanced and need to be
localized to the nucleus, need to heterodimerize, and need to
generate the different cohesin pools. Aberrant cell behavior or
pathologies may result if any of these requirements is not met,
which could occur naturally like in cohesin-related pathologies or
in experimental settings such as RNA interference approaches.
Therefore, we set out to determine the consequences of
manipulating the balance between SMC1 and SMC3 and
observed contrasting, protein-specific effects.
Materials and Methods
Cell culture conditions and drug treatment
HeLa cells, kindly provided by Dr. Frank Buchholz (MPI,
Dresden, Germany), were maintained in Dulbecco’s modified
Eagle’s medium (D-MEM) supplemented with 10% fetal calf
serum (FCS; InVitrogen/Gibco), penicillin and streptomycin in a
humidified atmosphere containing 5% CO2 in air. The EGFP-
msSMC1 or EGFP-msSMC3 stably expressing HeLa cell lines
were kindly provided by Dr. Ina Poser (MPI, Dresden, Germany).
Leptomycine B (LMB; Sigma) was used at 5 mg/mL and added for
2 h prior to cell harvesting.
DNA transfection and RNA interference
SMC1 is synonymous for SMC1A (SMC1a) in this commu-
ncation. For transient knock-down of SMC1 or EGFP-tagged
proteins HeLa cells were transfected with esiEGFP or esiSMC1
RNA (kindly provided by Dr. Frank Buchholz) with Oligofecta-
mine (Invitrogen). One ml of a 750 ng/mL of an esiRNA solution
per one million cells was used unless specified otherwise.
Alternatively, one mL of 50 pmol/mL of siSMC1, siSMC3 [34]
or non targeting siRNA solution [35] was used. The cells were
harvested 72 h post transfection unless indicated otherwise. The
bovine SMC1 (bSMC1) [36] was subcloned into the BglI/BamHI
site of pEGFP-C1. For transient DNA transfection 400,000 cells/
mL were transfected with 1 mg/mL EGFP-bSMC1, or untagged
bSMC1 in pCAGGS [37], or empty vector pEGFP-C1 (EGF-
Pempty) using Lipofectamine 2000.
Antibodies
Rabbit polyclonal antibodies against SMC1, SMC3, RAD21,
TopoII, were purchased from Bethyl Laboratories Inc. The
monoclonal mouse IgG1 ß-tubulin was from Sigma Inc. Rabbit
polyclonal anti-karypoherin-ß1 and anti-cPLA2 purchased from
Cell Signaling Technology. Goat polyclonal anti-EGFP antibody
was obtained from the MPI-CBG, Dresden, Germany. The HRP
conjugated secondary antibodies anti-goat, anti-rabbit or anti-
mouse used for immunoblotting detection were purchased from
Jackson Laboratory. Anti-mouse IgG1Alexa Fluor 488, anti-goat
Alexa 488 and anti-rabbit Alexa Fluor 555 used for immunoflu-
orescence were from InVitrogen and anti-mouse IgG2a FITC was
from Southern Biotech.
Cell lysates and western blot analysis
Cells for total protein extracts were harvested, washed twice
with PBS and lysed in RIPA buffer containing a protease inhibitor
cocktail (Roche, Mannheim, Germany). After incubation on ice
for 1 h the lysates were centrifuged at 14,000 g, 4uC, 15 min and
supernatants were collected. Nuclear and cytoplasmic extracts
were prepared from cells by detergent lysis. The cells were washed
twice with PBS, and resuspended in hypotonic buffer A (10 mM
TRIS pH 8.0, 1 mM EDTA, 100 mM NaCl) containing a
protease inhibitor cocktail (Roche, Mannheim, Germany), 2 mM
Na3VO4, 2 mM DTT, 1 mM NaF, 2 mM Na2S2O5 and 0.5 mM
spermidine. The swollen cells were treated with 2 mM MgCl2 and
0.1% NP-40 for 5 min on ice, and twice vortexed for 10 and 15 s,
with a 10 s interval. The cytoplasmic fraction was removed by
centrifugation at 4,000 rpm, 4uC, 3 min and the nuclei were
washed with buffer A and centrifuged again. After resuspension in
buffer B (10 mM TRIS pH 8.0, 1 mM EDTA) containing all
supplements as described for buffer A, 250 mM ammonium
sulfate was added and the lysates were incubated for 30 min on
ice. Following ultra-centrifugation at 40,000 rpm at 4uC for
30 min the nuclear supernatant was collected. For a most stringent
extraction, the pelleted nuclei were resuspended in RIPA buffer
for additional 30 min at 4uC and supernatants were collected
following centrifugation at 14,000 rpm and 4uC for 15 min.
Extractions with consecutively increasing concentrations of
ammonium sulfate (AS) were performed by resuspending the
nuclear pellets in buffer B without any AS (0 mM). After 10 min
incubation and centrifugation at 8,000 rpm at 4uC for 5 minutes
the supernatant was collected. The pellets were washed with buffer
B without AS and resuspended in buffer B containing 50 mM AS
and incubated for 10 min on ice. The supernatants (50 mM
Distinct Effects of SMC1 or SMC3 Manipulation
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nuclear extracts) were collected by centrifugation at 8,000 rpm,
4uC, 5 min. After washing the nuclei with buffer B without AS, the
pellets were resuspended in buffer B with 250 mM AS and
incubated on ice for 10 min. Supernatants were collected after
ultra-centrifugation at 40,000 rpm at 4uC for 30 min. For the final
extraction the remaining pellets were resuspended in RIPA buffer
for additional 30 min on ice and supernatants were collected
following ultra-centrifugation at 40,000 rpm and 4uC for 30 min.
Optionally, supernatants were subjected to immunoprecipitation
(0.1 to 1 mg lysate protein, 50 mL protein A or G agarose beads
(Invitrogen) with the indicated antibodies. Lysates or precipitated
proteins were analysed after gel electrophoresis by IB using
Hybond membranes (Amersham). For detection chemilumines-
cence (Pierce, ECL Western Blotting Substrate) was used. In some
instances, the protein gels were silver-stained.
Immunofluorescence microscopy
Cells cultured on cover slips were fixed with 3.7% formaldehyde
for 15 min, incubated with 0.5% Triton X-100 in PBS for 10 min
and with 3% fetal calf serum (FCS) for 1 h at RT. Primary
antibodies, diluted in 1% FCS/PBS were incubated for 1 h at RT.
Secondary antibodies were added for 30 min at 37uC diluted 1%
FCS/PBS. The cells were permanently mounted in FluormountG
(SouthernBiotech) for fluorescence microscopy (Axiophot, Zeiss)
and analysed by its relative software (Axiovision AxiVs40 V
4.6.3.0; Zeiss). To produce the final figures, the images were
transferred to Photoshop CS2 (Adobe Systems, San Jose, CA).
Identical illumination and camera settings were used within each
data set.
Figure 2. Characterization of cytoplasmic SMC3 protein. (A) Expression of mRNA of Smc1, Smc3 and Rad21 72 h after esiSMC1 treatment,
compared to control (esiEGFP), was examined by real-time RT-PCR. Relative quantification of gene expression was achieved by normalization to ß-
actin, (n = 3). (B) Effect of SMC1 knockdown on RAD21 protein in total RIPA extracts as monitored by IB with anti-Rad21 antibody 72 h post esiSMC1
or esiEGFP transfection. Bottom: quantification of IB from three independent experiments. (C) Sequential IP. IP #1 from nuclear and cytoplasmic
extracts from esiSMC1-treated and control cells. The supernatant was used for IP#2 with anti-SMC3 antibody. Eluates were analyzed by IB using anti-
RAD21, -SMC3, and -SMC1 antibodies. (D) Nuclear export was inhibited 70 h after esiSMC1 or control treatment by addition of LMB to a final
concentration of 5 ng/mL for another 2 h. The localization of SMC3 (in red, top half) was examined by immunofluorescence. NFkB (in red, bottom
half) was used to confirm the LMB effect. DNA was visualized by DAPI (in blue). (E) Immunoprecipitation of SMC3 from cytoplasm and nuclear extracts
after LMB inhibition was performed and eluates examined by silver staining. Arrows indicate the positions of SMC1, SMC3 and RAD21. The asterisk
indicates an unspecific band as specified by mass spectrometric analysis.
doi:10.1371/journal.pone.0065149.g002
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mRNA isolation and PCR
The mRNA was isolated using the RNeasy Mini Kit (Qiagen)
including DNAse digestion using RNase-free DNAse Set (Qiagen).
The cDNA was generated by Superscript II Reverse Transcriptase
(InVitrogen). Primer sequences for Smc1 were: forward 59-
CAAGTTCGAGAGCAAAGCGG-39 and reverse 59-
TTCCTCCCAGAAACACACCAAG-39, for Smc3 forward 59-
GGAGGGCAGTCAGTCTCAAG-39, reverse 59-AG-
CAAGGGCTACCAAGGATT-39 and for Rad21 forward 59-
CAAATTGACCCAGAGCCTGT-39, reverse 59-CCCTGATG-
CATCTTCATCCT-39. The cDNA was quantified by real-time
qRT-PCR using QuantiTect SYBR Green PCR Kit (QIAGEN).
For normalization of cDNA data, the ß-actin gene product was
used with the primer sequences: forward 59-
CTCTTCCAGCCTTCCTTCCTG -39 and reverse 59- AG-
CACTGTGTTGGCGTACAG -39. All oligonucleotides were
from Eurofins MWG Operon (Ebersberg, Germany). Expression
levels were calculated using Rotor Gene software 3000 (Corbet
Research Inc.) and related to the mock or control-treated cultures.
Melting point curve analysis resulting in homogenous signals
verified the specificity of the primer. In addition, cDNA was
analysed by PCR using the same primer pairs and conventional
PCR and Dream Taq Polymerase (Fermentas) following agarose
gel electrophoresis.
Cell cycle analysis
The cells were harvested, washed twice with PBS and fixed in
70% Ethanol at 220uC. After rehydration and blocking in PBS
containing 2% FCS and 2 mM EDTA the cells were incubated
with 100 ng/mL RNAse at RT. The cells were then stained with
Figure 3. Differential salt extraction from control or esiSMC1-treated cells. Representative results from three independent experiments are
shown. (A) Nuclear extracts from esiSMC1 and control treated cells were prepared by successive treatment with increasing salt (0 mM, 50 mM,
250 mM ammonium sulfate) concentrations. After the last salt extraction RIPA buffer was used for the final extraction step. IB analysis for SMC3, SMC1
and RAD21 followed. Topo II was used as nuclear loading control, cPLA2 as a cytoplasmic control, and for a loading control of all fractions
karyopherin (k) ß1 was used. (B) Quantification of the relative distribution of SMC1, SMC1 and RAD21 in different nuclear fractions after esiEGFP (top)
or esiSMC1 (bottom) treatment as presented in A. (C) IP with anti-SMC3 or (D) anti-SMC1 antibodies was done with all fractions and eluates were
examined by silver staining. The asterisk indicates the unspecific band described in 2D.
doi:10.1371/journal.pone.0065149.g003
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propidium iodine (Sigma-Aldrich) at 50 ng/mL and the cell cycle
status was analyzed by flow cytometry on an LSRII analyzer (BD
Bioscience).
FRAP
FRAP Measurements and analyses were performed as described
previously [38] with few modifications. Cell cultures and siRNA/
esiRNA tretament was done as described above. FRAP experi-
ments were performed with a Leica TCS SP5 using the 488 nm
laser line of an Argon laser (3.01 mW), a HeNe-Laser at 594 nm
(0.59 mW) and a 405 nm Laser Diode (4.63 mW) at 37u. For
acquiring the pre- and post-bleaching images the 488 nm Line was
used with 10% power. A circular ROI with a diameter of 6 mm in
the nucleus was selected and bleached for 1.25 s with maximal
power from all lasers. 10 images were acquired before bleaching
and 250 images were continuously acquired afterwards for further
80 s. To quantitatively analyze the fluorescence recovery process,
background fluorescence was subtracted from all images, and the
fluorescence of the bleached ROI was normalized to the total
fluorescence intensity of the whole nucleus. The resulting curve for
the normalized intensity I(t) was fitted with a Levenberg-
Marquardt-algorithm to the following exponential function (1)
(using a self-written LabView-Program) with the fitting parameters
Mf, t and I0: (1) I(t) = Mf2(Mf 2I0) (exp(2t/t)), where Mf is the
mobile fraction, t the time constant for the recovery process and I0
is the normalized fluorescence intensity of the ROI immediately
after bleaching.
Statistical analysis
IB images, analyzed by ImageJ (Version 1.42a, standard plug-
ins) and the resulting values or values obtained by real-time PCR
and eppendorf vapo protect (Eppendorf, Hamburg, Germany)
were transferred to Microsoft Excel. The statistical analysis was
carried out using the two-tailed paired t test and p values ,0.05
were considered to be statistically significant (*).
Proliferation assay
Living cells used for proliferation assays were stained with
10 mM CFSE (Cell Trace CFSE cell proliferation kit, Molecular
Probes) for 15 minutes at 37uC in culture medium and further
processed according to the manufacturers protocol. The prolifer-
ation status was analyzed at indicated time points by flow
cytometry (BD Bioscience).
Results
SMC1 knock-down causes cytoplasmic mis-localization of
SMC3
To examine the fate of SMC3 that largely lacks its SMC1
heterodimerization partner, esiRNA [39] was used to transiently
knock-down human SMC1 (‘‘esiSMC1’’). To establish an effective
esiRNA concentration and the kinetics of its effect, total cell
extracts from HeLa cells treated once for 72 h with different
concentrations of esiSMC1 (500, 750 and 1000 ng/mL per 16106
cells) were analyzed by immuno blotting (IB) using anti-SMC1
antibody (Fig. 1A). SMC1 protein level was not affected in mock
treated cells. At 750 ng/mL transfected esiSMC1 an SMC1
knockdown to 31% was observed and was used in subsequent
experiments. A decrease in SMC1 protein levels was observed
starting 24 h after a single transfection (Fig. S1A) and maximal
SMC1 protein reduction to 16% was observed at 72 h (Fig. 1B
and S1A). At 144 h after transfection, SMC1 has recovered to
levels close to those seen before treatment (Fig. 1B). At 750 ng/mL
esiSMC1 and the 72 h time point, SMC1 protein was in average
reduced to 30% (610%) compared to cells treated with esiEGFP
esiRNA (Fig. 1C; n = 7). At a transfection efficiency of about 80%,
SMC1 levels in the transfected cells are certainly below the 30%
mark, which included the 20% non-transfected cells. SMC3
protein levels remained largely unchanged upon SMC1 knock-
down (Fig. 1A–C) – a small decrease occasionally observed was not
statistically significant – demonstrating the specificity of esiSMC1
treatment and suggesting stability of SMC3 even in absence of
SMC1. Immunofluorescence (IF) analyses of SMC1 after esiSMC1
treatment showed very weak nuclear signals in most of the cells
(Fig. 1D). Some non-transfected cells are present and show strong
nuclear SMC1 staining, which serves as positive staining control.
No cytoplasmic staining was observed. Treatment with control
esiEGFP showed no effect on SMC1 staining (Fig. 1D).
Neither measurable changes in proliferation and cell cycle
progression (Fig. S1B, S1C) nor increased sensitivity to DNA
damaging drugs such as mitomycine C (MMC) (Fig. S1D) were
observed in cells treated with esiSMC1 as described above. The
Figure 4. IF analysis of transiently over-expressed bovine
SMC1 (EGFP-bSMC1) in HeLa cells. Anti-SMC1 antibody (red) and
EGFP (green) were used. Nuclear staining was obtained using DAPI
(blue) (A) 24 h after transfection of bovine SMC1 without any tag or N-
terminally tagged EGFP-bSMC1. As a control an EGFP-empty vector was
used. Anti-SMC1 antibody (red) stains both, tagged and non-tagged
SMC1 proteins. (B) Stability of transiently overexpressed EGFP-bSMC1
(green) 24, 48 and 72 h after transfection.
doi:10.1371/journal.pone.0065149.g004
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kinetics of ATM catalyzed phosphorylation of H2AX to cH2AX,
or of SMC1 at S-957 [40,41], the formation of SMC6 foci, and
levels of apoptosis remained normal (Fig. 1D, 1E, and data not
shown), as do long-term cell cycle profiles (Fig. 2A). This indicates
that for these core functions of cohesin, less than 30% of cohesin is
required.
Since total protein levels of SMC3 remained largely unchanged
upon SMC1 knockdown, we investigated the intracellular
localization of SMC3 after esiSMC1 or esiEGFP transfection.
Surprisingly, upon SMC1 knockdown a large portion of SMC3
appeared in the cytoplasm, while its nuclear staining remained
unchanged (Fig. 1E–H). Control treatments with esiEGFP did not
alter the distribution of SMC3 (Fig. 1E–G). IB of cytoplasmic and
nuclear extracts confirmed the IF data and showed a strong
increase in cytoplasmic SMC3 specifically upon SMC1 knock-
down. A very weak signal for SMC1 and SMC3 in the cytoplasmic
extracts in control cells very likely results from unavoidable
nuclear protein contamination (Fig. 1F). In average the cytoplas-
mic SMC3 protein level was increased to 500% (6200%) over the
basal (background) level (100%) of control treated cells (n = 4).
Only a slight, if any, decrease of nuclear SMC3 was observed in
esiSMC1 treated cells (Fig. 1F). The nuclear SMC1 protein level in
esiSMC1 treated cells was significantly reduced to 40% (620%) of
mock treated or untreated cells (100%) (Fig. 1G). Two different,
independent siRNA sequences specific for human SMC1 were
used and yielded very similar results (Fig. 1H and Fig. S2B). The
kinetics of cytoplasmic SMC3 localization following siSMC1
treatment follows the pattern seen in esiSMC1 treatment: strong
cytoplasmic signals for SMC3 at 72 h post treatment, and decrease
of cytoplasmic staining starting around 96 h and eventually full
recovery of nuclear staining at 192 h (Fig. 1H).
These data indicate the continued presence of a small fraction of
nuclear cohesin, probably required to maintain essential functions,
Figure 5. Two-species system: knockdown of human SMC1 by esiRNA and rescue by over-expression of bovine SMC1 (EGFP-
bSMC1). (A) Scheme of esiSMC1 and plasmid DNA transfection. (B) Nuclear localization of EGFP-bSMC1 (green) and rescue of SMC3 mis-localization
by anti-SMC3 staining (red) 72 h after esiSMC1 and 24 h EGFP-bSMC1. The arrows indicate nuclear localization (large arrow) of SMC3 and EGFP-
bSMC1 (rescue) or cytoplasmic localization (arrowhead) for both (no rescue). The EGFP-empty vector (right) was used as control. (C) Using anti-EGFP
antibody for IB analysis of total cell extracts (RIPA), the efficiency of EGFP-bSMC1 expression upon esiSMC1 and esiEGFP was monitored. The
percentage of EGFP-bSMC1 levels was normalized to ß-tubulin as a loading control. The SMC1 knock-down was confirmed using anti-SMC1 antibody.
(D) Nuclear localization of EGFP-bSMC1 (green) 48 h after transfection with EGFP-bSMC1 of esiSMC1-treated cells. Nuclear SMC3 is shown using anti-
SMC3 antibody (red). The arrows indicate rare nuclear localization of EGFP-bSMC1 in cells not treated with esiSMC1 and much more nuclear EGFP-
bSMC1 localization in cells treated with esiSMC1. (E) Rescue of SMC3 distribution seen with anti-SMC3 antibody (red) 72 h after co-transfection of
esiSMC1 and EGFP-bSMC1. The DNA was visualized in each case using DAPI (blue). (F) Total cell extracts (RIPA) prepared from cells transfected for
48 h with EGFP-bSMC1 and 72 h esiSMC1 treatment. IB analyses used anti-SMC3, -EGFP or -SMC1 antibodies. Percentages of EGFP-bSMC1 expression
are shown at the bottom.
doi:10.1371/journal.pone.0065149.g005
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and a large cytoplasmic accumulation of SMC3 when its partner
SMC1 is mostly absent.
Does cytoplasmic SMC3 form cohesin complexes?
One explanation for the appearance of cytoplasmic SMC3
could be aberrant up-regulation of Smc3 gene expression in
response to SMC1 knock-down. Hence, the mRNA expression of
Smc1, Smc3 and Rad21 was examined by real-time RT-PCR
(Fig. 2A). Relative quantification was achieved by normalization to
ß-actin and comparison to esiEGFP treated cells. The data
confirm reduction of Smc1 mRNA after esiSMC1 treatment and
show unaltered Smc3 gene expression. A significant increase of
Figure 6. SMC3 knock-down by siRNA reduces the stability of SMC1. (A) Time course of reduction and recovery of SMC3 analyzed by IF
microscopy with anti-SMC3 (in red) and DAPI (in blue). (B) IF analysis using antiSMC1 antibody (in red) and DAPI (in blue). (C) Quantification of three
independent IB experiments using total cell extracts (RIPA) after siSMC3 treatment. (D) Expression of mRNA of Smc1, Smc3 and ß-actin 72 h after
esiSMC1, siSMC1, or siSMC3 treatment, compared to control (esiEGFP), was examined by RT PCR and agarose gel electrophoresis. (E) Cytoplasmic,
nuclear and total cell extracts (RIPA) were prepared 72 h after transfection with esiEGFP, esiSMC1, siSMC1, siSMC3, or non targeting siRNA control.
Protein amounts were analyzed by IB using anti-SMC1, anti-RAD21 and anti-SMC3 antibodies. Topo II was used as a nuclear control and cPLA2 as a
cytoplasmic loading control. (F) 48 h after siSMC3 or esiSMC1 treatment the cells were transfected with EGFP-bSMC1 for further 24 h. The localization
of EGFP-bSMC1 was analyzed by IF microscopy using anti-EGFP antibody.
doi:10.1371/journal.pone.0065149.g006
Distinct Effects of SMC1 or SMC3 Manipulation
PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e65149
Rad21 gene expression was observed, possibly in an attempt by the
cell to complement loss of RAD21, since levels of RAD21 protein
were reduced to 40% (610%) in esiSMC1 treated cells (Fig. 2B).
Thus, the reduction of SMC1 affects not only SMC3 localization,
but also the presence of RAD21 protein, which in absence of
sufficient SMC1/SMC3 partners is probably degraded.
Cytoplasmic SMC3 that appears upon SMC1 knock-down may
exist without associated cohesin subunits – there is certainly not
sufficient SMC1 available for dimerization. Two consecutive
rounds of immuno precipitation (IP) were used to determine the
molecular status of the excess cytoplasmic SMC3. Residual
cytoplasmic and nuclear extracts used once for immuno precip-
itation (IP) with anti-SMC1 (IP #1) were used for a second IP (IP
#2) with anti-SMC3 antibody. Precipitates were analyzed by IB
(Fig. 2C). As expected no SMC3, SMC1 or RAD21 was detected
in anti-SMC1 IP from cytoplasmic extracts, either in esiSMC1
(lane 1) and only very little, if any, in esiEGFP (lane 2) treated cells.
The decreased SMC3 signal in anti-SMC1 IP from nuclear
extracts from esiSMC1 treated cells (lane 3) confirms the strongly
reduced presence of SMC1/SMC3 complexes in nuclei. Similarly,
the SMC1 signal is strongly decreased in IPs from nuclear extract
of esiSMC1 treated cells (lane 3 to compare with 4), as are levels of
SMC3 and RAD21. Re-precipitation of the supernatants with
anti-SMC3 showed that SMC3 is present without associated
SMC1 or RAD21 in the cytoplasm of esiSMC1 treated cells (lane
5). No SMC3 is seen in the corresponding fraction from esiEGFP
treated cells (lane 6). A large portion of SMC3 is still visible in anti-
SMC3 re-precipitates from the nuclear extract supernatants of
esiSMC1 treated, but less is precipitated from supernatants of
esiEGFP treated cells (lane 7 and 8). This indicates that there is
also some excess of SMC3 in the nuclei of esiSMC1-treated cells.
This is consistent with the reduction of SMC1 and RAD21 in anti
SMC3 re-precipitates from esiSMC1 treated cells.
The cytoplasmic mis-localization of SMC3 in absence of most
SMC1 raises the question, whether SMC3 without its SMC1
partner was initially imported into the nucleus and then released in
the cytoplasm or stayed in the cytoplasm without ever translocat-
ing into the nucleus. In the latter case, blocking of export of SMC3
from the nucleus would not reduce the cytoplasmic accumulation
of SMC3 in esiSMC1 treated cells. Human, mouse and bovine
SMC3 harbor a conserved leucine-rich nuclear exit signal (NES) at
position 1023–1028. Nuclear export was inhibited by Leptomycine
B (LMB), which was added for two hours at 70 h after esiSMC1 or
esiEGFP treatment. The distribution of SMC3 examined by IF
and was not visibly altered (Fig. 2D). For a positive control NFkB
distribution after LMB treatment was assessed. NFkB strongly
accumulated in the nucleus upon LMB treatment (Fig. 2D,
bottom). Additionally, anti-SMC3 IP from cytoplasmic and
nuclear extracts after esiSMC1 or esiEGFP treatment and LMB
inhibition were examined by silver staining. No differences in
signals were observed upon LMB treatment in SMC1, SMC3 or
RAD21, neither in esiEGFP or esiSMC1 treated cells (Fig. 2E).
Besides, no obvious differences were seen in SMC3 mobility in
SDS-PAGE between cytoplasmic (lanes 1–4) and nuclear SMC3
(lanes 7–10), and thus there is no obvious indication for extensive
posttranslational modifications of cytoplasmic SMC3 in SMC1
knock-down cells.
Excess nuclear SMC3 barely associates with chromatin
The above data suggest the cytoplasmic SMC3 protein in
esiSMC1 treated cells does not translocate to and from the
nucleus. However, there is still nuclear SMC3 at levels that are
Figure 7. Two-species system: knockdown of human SMC3 by siRNA and rescue by stably expressed EGFP-msSMC3. (A) Cells stably
transfected with EGFP-msSMC3 were analyzed by IF microscopy. (B) Total cell (RIPA), cytoplasmic and nuclear extracts from cells stably expressing
EGFP-msSMC3 collected 72 h after treatment with siSMC1 or siSMC3 were analyzed by IB using anti-EGFP, -SMC3 and -SMC1 antibodies. RIPA buffer
was used for the final extraction step after the nuclear extraction with 250 mM ammonium sulfate. Topo II and Karyopherin ß1 were used as a loading
control. Relative protein levels are shown at the bottom (representative of 3 experiments).
doi:10.1371/journal.pone.0065149.g007
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unchanged upon SMC1 knock-down, although SMC1 and
RAD21 are strongly reduced. For the lack of partners, this excess
nuclear SMC3 is most likely not incorporated into cohesin
complexes (Fig. 2C, lane 7), but does such excess nuclear SMC3
stably associate with chromatin? Nuclei from esiSMC1 and
esiEGFP treated cells were extracted by three consecutive salt
concentrations of 0 mM, 50 mM, and 250 mM ammonium
sulfate (AS) to elute protein fractions with increasing affinity to
chromatin (Fig. 3A, B). The remainder of the thrice-extracted
nuclei was finally extracted with RIPA buffer. In controls,
cytoplasmic and total extracts showed the cytoplasmic appearance
of SMC3 as well as the reduction of SMC1 and RAD21
specifically in SMC1 knock-down cells (lanes 9–12). TopoII was
used as a nuclear and total extract loading control (lanes 5,6 and
11,12) and cPLA2 as a cytoplasmic control (lanes 9,10) to assess
the purity of nuclear extracts. As a loading control for all fractions
karyopherin ß1 was used.
Only a small decrease of 4% of total SMC3 was seen upon
SMC1 knockdown, but total amounts of SMC1 and RAD21 were
decreased by 54% and 48% resp. as indicated in Fig. 3B, bottom
graph, when compared to their levels in esiEGFP treated cells
(100%). Only very little nuclear SMC3, SMC1 and RAD21 eluted
at 0 mM AS from esiEGFP cells (lane 1). However, a much larger
portion (21%) of nuclear SMC3, but not of SMC1 and RAD21,
elutes at 0 mM after esiSMC1 treatment of the cells (lane 2).
Correspondingly, the high salt-eluted fraction of SMC3 from
esiSMC1 treated cells is reduced from 32% to 14%. Thus, a
considerable pool of excess SMC3 does not or only very weakly
bind chromatin if SMC1 is scarce. The disproportionally larger
reduction of SMC1 and RAD21 (to 1.7% and 4% respectively)
that elutes at 0 mM may indicate that the non chromatin-
associated pool is the one that can be most easily reduced in
esiSMC1-treated cells. Most SMC3, SMC1and RAD21 (.50%)
elutes from the nuclei at 50 mM AS (lane 3) after esiEGFP (lane 3).
In esiSMC1 treated cells this fraction of SMC3 is unchanged
(52%). Of the remaining SMC1 and RAD21, 66% and 46%,
respectively, elute at 50 mM (31% and 24% of the pre-treatment
amounts), and thus also an unchanged proportion of these two
cohesins elutes at 50 mM salt. Between 26% and 32% of SMC3,
SMC1 or RAD21 eluted at 250 mM (lanes 5,6), and this fraction is
generally decreased about 2-fold in esiSMC1-treated cells.
However, the fraction that requires the most stringent extraction
conditions, the RIPA fraction, is increased for SMC1 (4-fold from
4.2% to 18% of the remaining SMC1) and RAD21 (2-fold from
9.9% to 21% of the remaining RAD21), but not for SMC3.
These data demonstrate that much of the excess nuclear SMC3
does not or only very weakly associate with chromatin and
supports the above conclusion of the non-cohesion role of excess
SMC3 in both, the nucleus and the cytoplasm. The data also
suggest that in esiSMC1-treated cells the small fraction of
remaining cohesin including SMC1 and RAD21 associates with
particular high affinity with chromatin.
Furthermore, anti-SMC1 and anti-SMC3 IPs were performed
from all differentially extracted nuclear fractions and the eluates
were examined by silver staining (Fig. 3C, D). Anti-SMC3 IP
(Fig. 3C) from 0 mM AS extracts yielded weak SMC1 and SMC3
bands, but in very similar intensities from esiSMC1 as from
esiEGFP treated cells (lane 1). The corresponding IP from
esiSMC1 cell extracts (lane 2) shows almost only the SMC3 band,
which is slightly stronger. A similar pattern from esiSMC1 cells is
seen at 50 AS (lanes 3 and 4) as well as at 250 AS: weaker SMC1
and disproportionally stronger SMC3, which in the 250 mM AS
extract shows two bands close to each other. The nature of these
bands, possibly posttranslationally modified forms, may be
determined in future experiments. No differences between
esiEGFP and esiSMC1 were observed in RIPA fractions (lanes 7
and 8), where a 1:1 SMC1/SMC3 pattern is seen, suggesting that
this constitutes the remainder of the cohesin, which binds with
highest affinity. As above, the prominent band appearing below
SMC3 is unspecific. The results are in agreement with data above
(Fig. 1E, F and 2F), which show continued presence of some excess
SMC3 in the nucleus of SMC1 knock-down cells.
In accordance with Figure 3A, the anti-SMC1 IP (Fig. 3D)
generated essentially no signal from the 0 mM AS esiSMC1 cell
nuclear extract (lane 10), again indicating that the most loosely
chromatin-associated fraction of SMC1 is absent under SMC1
knock-down conditions. In all subsequent extracts, an approxi-
mately 1:1 ratio of SMC1 and SMC3 was observed (lanes 11–16)
with the expected reduced SMC1/SMC3 signal upon SMC1
knock-down (lanes 12 and 14). No difference between control and
esiSMC1 samples is seen in the RIPA sample (lanes 15 and 16),
confirming the presence of a relatively small amount of the
heterodimer in this most tightly chromatin-associated fraction.
This suggests, the soluble, less tightly or not chromatin-associated
pool of cohesin is the most expendable.
Transiently over-expressed SMC1 remains cytoplasmic
and is only marginally incorporated into cohesin
The above experiments indicate the 1:1 stoichiometry between
SMC1 and SMC3 proteins is critical. Thus, over-expression of
SMC1 or SMC3 may also elicit distinct phenotypes. SMC proteins
are ubiquitous and evolutionary highly conserved and thus we
used EGFP-bSMC1 (bovine), which is nearly identical to human
SMC1 (99.8% amino acid identity) in a two-species-system, which
allows further manipulations. The functionality of EGFP-bSMC1
in human cells is demonstrated in the following section.
Transiently over-expressed EGFP-tagged like untagged bSMC1
largely failed to localize to HeLa cell nuclei, but rather strongly
accumulated in the cytoplasm (Fig. 4A). Transfection of EGFP
control vector (EGFPempty) did not alter the pattern of
endogenous SMC1 staining. The stability of over-expressed
EGFP-bSMC1 declines beyond 24 h after transfection and the
protein is absent 72 h after transfection (Fig. 4B).
Functional complementation of down-regulated hSMC1
by exogenous bSMC1 in a two-species system
Next we asked, whether EGFP-bSMC1 can functionally
complement depletion of endogenous SMC1 after esiSMC1
treatment of HeLa cells. We exploited the divergence of the
DNA and RNA sequences in this two-species system. The
experimental scheme is shown in Figure 5A and indicates the
different time points of DNA transfection after esiRNA treatment.
The esiSMC1 reagent for human SMC1 does not affect EGFP-
bSMC1 at any time point (Fig. 5B–E). The EGFP-bSMC1 or
EGFP vectors were transfected into the cells for expression for 24,
48, or 72 h. EsiSMC1 was present throughout the 72 h period. At
24 h after EGFP-bSMC1 transfection and 72 h after SMC1
reduction, IF (Fig. 5B) and IB analyses (Fig. 5C) were performed.
Functional complementation was achieved for both phenotypes in
that increased nuclear localization of EGFP-bSMC1 and partial
rescue of the cytoplasmic mis-localization of SMC3 were observed
(Fig. 5B, left). The EGFP control vector did not produce any of
these effects. The effectivity of esiRNA was confirmed using
esiEGFP, which targets EGFP-bSMC1 or EGFP mRNA for
degradation (Fig. 5B, right). The EGFP signal was in each case
heavily reduced upon esiEGFP treatment (to 18% for EGFP-
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bSMC1), and endogenous SMC1 and SMC3 protein levels and
distribution remained unchanged (Fig. 5B, C).
The EGFP-bSMC1 protein level was moderately increased to
117% if esiSMC1 was used (Fig. 5C), perhaps because more
SMC3 was available to dimerize with EGFP-bSMC1 to stabilize
it. Intense nuclear localization of EGFP-bSMC1 was seen 48 h
after EGFP-bSMC1 transfection into esiSMC1 treated cells
(Fig. 5D, fourth row). The relatively low percentage of green cells
results from the limited efficiency of the consecutive double
transfection of esiRNA and plasmid, but even cells less bright for
the GFP signal may express low levels of the exogenous EGFP-
bSMC1. The rescue of SMC3 nuclear localization was more
pronounced at 48 h and 72 h than at 24 h after EGFP-bSMC1
transfection (compare Fig. 5B with 5D, 5E). However, in cells
transfected with EGFP-bSMC1 but not with esiSMC1, most of the
cytoplasmic EGFP-bSMC1 was degraded and barely visible in the
cytoplasm or nucleus 48 h after transfection (Fig. 5D, second row).
This is consistent with the data showing strong reduction of
cytoplasmic EGFP-bSMC1 48 h and 72 h after plasmid transfec-
tion (Fig. 4B) and indicates that – different from excess SMC3 –
excess SMC1 is not stable. Co-transfection of esiSMC1 and
EGFP-bSMC1 almost completely rescued the nuclear localization
of SMC3 (Fig. 5E; 72 h). The EGFP-bSMC1 signal was decreased
when compared to the 48 h image and only detectable in the
nucleus (Figure 5E).
Together this suggests that excess SMC3 supports nuclear
localization of excess SMC1, that nuclear localization of SMC1 (in
association with SMC3) prevents its degradation, and that excess
SMC1 is instable.
Since the most intense nuclear EGFP-bSMC1 staining was seen
48 h after EGFP-bSMC1 transfection into cells that were treated
for a total of 72 h with esiSMC1, we used these conditions for
further analysis. Total cell extracts were obtained 72 h after
esiSMC1 or mock treatment with or without expression of EGFP-
bSMC1 for the final 48 h (‘‘72/48 h cells’’ as in D). These total
cell lysates (RIPA) were initially analysed by IB using anti-SMC3
and showed largely unchanged levels of SMC3 in protein in all
samples (Fig. 5F). Reprobing the same membrane with anti-EGFP
antibody revealed only a weak signal (27%) for EGFP-bSMC1 in
cells not treated with esiSMC1 and a much stronger signal in
esiSMC1 treated cells (100%). The data are consistent with the
above IF results showing stabilization of EGFP-bSMC1 upon
knock-down of endogenous SMC1. The knock-down of endoge-
nous human SMC1 is not affected by expression of EGFP-bSMC1
(Fig. 5F; two right lanes, bottom blot). IP experiments showed
complex formation of EGFP-bSMC1 with SMC3 in untreated and
esiSMC1-treated cells (data not shown).
SMC3 knock-down triggers degradation of SMC1 and
RAD21
Considering the SMC3 mis-localization reported above for
esiSMC1 treated cells, we investigated whether SMC3 knock-
down has a similar effect on SMC1. Two different SMC3 siRNAs
were tested and behaved similarly. The kinetics of reduction and
recovery of SMC3 following siSMC3 #1 was analyzed in detail by
IF using anti-SMC3 (Fig. 6A) and IB from total RIPA extracts
(Fig. S3A) and are comparable to that of SMC1 knock-down.
Similar to the effects of SMC1 knock-down, cell cycle progression
was not affected by siSMC3 treatment (Fig. S3A, B). IF analysis
using anti-SMC1 antibody revealed loss of SMC1 following
siSMC3 treatment (Fig. 6B). Quantification of IB analysis
confirmed knock-down of SMC3 by three-fold and the parallel
loss of SMC1 to about half (Fig. S3A, Fig. 6C), whereas the
mRNA of SMC1 is only mildly affected (Fig. 6D). Further,
cytoplasmic, nuclear and total cell extracts obtained 72 h after
transfection with esiEGFP, esiSMC1, siSMC1, siSMC3 or an
unspecific siRNA control were analyzed by IB using anti-SMC1,
anti-RAD21 and anti-SMC3 (Fig. 6E). The results demonstrate
specific effects upon SMC3-siRNA treatment on SMC1 and
RAD21, which become instable. Thus, in contrast to SMC1,
which controls SMC3 localization but not stability, SMC3 is
required for SMC1 stability.
Expression of EGFP-bSMC1 for 24 h upon SMC3 knock-down
(72 h) did not rescue the loss of endogenous SMC1, and the
EGFP-bSMC1 localized in the cytoplasm of siSMC3-treated cells,
but in the nucleus and cytoplasm of esiSMC1-treated cells (Fig. 6F).
We therefore hypothesize that SMC3 is involved in SMC1 nuclear
import.
Rescue of siSMC3-induced phenotypes by expression of
EGFP-msSMC3
The above data showed that a two-species system functions in
complementing effects of the SMC1 knock-down. To rescue the
SMC1 instability caused by hSMC3 knock-down, we used a HeLa
cell line that stably expresses EGFP-tagged mouse SMC3 (EGFP-
msSMC3). Using anti-EGFP in IF (Fig. 7A, mock treated cells)
and IB (Fig. 7B, lane 1) we observed an about equal cytoplasmic
and nuclear distribution of EGFP-msSMC3. The endogenous
SMC3, similar to SMC1, remains normally localized in the
nucleus (Fig. 7B, lane 4). Cytoplasmic EGFP-msSMC3 was 4-fold
increased following siSMC1 treatment (Fig. 7A and 7B, lane 2), in
agreement with the above data from esiSMC1 experiments.
Because a large portion of endogenous hSMC3 is also distributed
to the cytoplasm upon SMC1 knock-down (Fig. 7B, lane 2; 5-fold
increase), SMC1 knock-down similarly affects both, hSMC3 and
EGFP-msSMC3. Upon human SMC3 knock-down by siRNA to
about 50%, the nuclear EGFP-msSMC3 was app. 1.5-fold
increased (Figure 7B, lane 6). Thus, EGFP-msSMC3 is not
affected by human siSMC3 and replaces the reduced hSMC3.
Moreover, this replacement is functional since it prevented the
degradation of endogenous human SMC1 and RAD21 (Figure 7B,
lane 6).
Furthermore, RIPA extraction of nuclei after their initial salt
extraction revealed that EGFP-msSMC3 did bind with high
affinity to chromatin only after siSMC3 treatment (Figure 7B, lane
9), confirming EGFP-msSMC3 functionally replaces hSMC3.
Since in the most tightly chromatin-bound fraction, SMC1 and
SMC3 exist as heterodimers, and SMC1 is present in the post
nuclear RIPA fraction (lane 9), EGFP-msSMC3 became part of
that complex.
Dynamics of Nuclear Cohesin Recovery
To assess the dynamics of EGFP-msSMC1 in HeLa cells,
treated with human esiSMC1, siSMC3, or left untreated, we used
FRAP (fluorescence recovery after photobleaching) (Fig. 8A). After
a circular region with a diameter of 6 mm of individual nuclei for
1.25 s, the fluorescence recovery was measured for 80 s and
reached, in average, levels between 60 and 80% of starting
fluorescence. When compared to data from figure 3, this suggests
that the mobile fraction corresponds to the pools extracted with
0 mM, 50 mM and partially 250 mM AS, while the immobile
Fraction corresponds to some of the 250 mM AS extracts and the
RIPA extracts.
The intensity of after recovery of EGFP-msSMC1 was
significantly different between cells were treated with either
esiSMC1 or siSMC3 in that reduction of endogenous SMC1
allowed more EGFP signal to reappear than reduction of SMC3.
Having insufficient amounts of SMC3 available restricts the
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presence of EGFP-msSMC1, consistent with the instability of
SMC1 after SMC3 knockdown. The velocity constant t as an
indicator for the mobility of the EGFP-bSMC1 protein was found
increased after esiSMC1 and after siSMC3 treatment, which
indicates reduced mobility. In the absence of endogenous SMC1
or SMC3, the transgenic msSMC1 may become more firmly
associated with chromatin.
Similarly, the dynamics of EGFP-msSMC3 in HeLa cells was
analyzed. Signal recovery after bleaching was 60 to 80% here as
well. In contrast to EGFP-msSMC1, the intensity of EGFP-
msSMC3 increased most if endogenous SMC3 was decreased,
which indicates replacement of the endogenous SMC3 by the
msSMC3. The mobile fraction of msSMC3 was lowest in siSMC3
treated cells, suggesting that the msSMC3 became incorporated
into the more tightly chromatin-associated cohesion fraction.
Without much of an SMC1 partner available in the esiSMC1-
treated cells, the amount of EGFP-msSMC3 monomers was
increased, resulting in enhanced mobility.
Discussion
The SMC1/SMC3 heterodimer constitutes the essential back-
bone of the ring-like cohesin complex. The two SMC proteins are
present in an 1:1 stoichiometry and supposedly do not exist on
their own or outside the nucleus in any significant or biologically
meaningful manner. It was unclear, however, how the behavior of
each of these SMC proteins depends on the presence of the other.
To elucidate that dependency we set out to manipulate the
balance between these SMC proteins by individually reducing
their presence in human cells. Unexpectedly, these studies
revealed specific and different effects on each of the SMC proteins.
In particular, we show that (1) under conditions of SMC1
scarcity, SMC3 remained stable and heavily accumulated in the
cytoplasm without SMC1 or RAD21 associated; (2) the excess
SMC3 that stayed in the SMC1-reduced nucleus is not or only
very weakly chromatin-associated; (3) with SMC3 deprived,
SMC1 became highly instable; (4) the remaining endogenous
SMC1 or SMC3 in the respective knock-down experiments
associated with its SMC partner and with RAD21 and constituted
the high-affinity chromatin associated fraction; (5) expression of
bovine or mouse SMC1 or SMC3 rescued the phenotypes seen
upon paucity of endogenous human SMC1 or SMC3; (6)
transiently overexpressed SMC1 or stably expressed SMC3 in
otherwise untreated cells mostly mis-localized to the cytoplasm, to
be rescued only by down-regulation of endogenous SMC1 or
SMC3. Decreased mobility of EGFP-tagged SMC3 in case of
reduced levels of endogenous SMC3 as seen in FRAP experiments
fit to this notion as the EGFP-SMC3 replaces endogenous SMC3
in the tightly chromatin-associated fraction. Similarly, the highly
mobile fraction of EGFP-SMC1 decreased when endogenous
SMC1 was down-regulated. When SMC3 was reduced, the
mobile fraction of EGFP-SMC1 became instable, was degraded
due to lack of a partner, and the tightly chromatin-associated
fraction increased relatively, explaining the decrease in EGFP-
SMC1 mobility upon SMC3 knock-down.
Consistent with these observations, nuclear SMC1 was more
stable than mis-localized cytoplasmic SMC1, and excess exoge-
nous SMC3 supports nuclear localization of excess SMC1 under
conditions of reduced endogenous SMC3.
Figure 8. FRAP experiments using EGFP-msSMC1 (A) or EGFP-msSMC3 (B) as bleach substrates. The mobile fraction (recovery), the
intensity of the EGFP-tagged protein signal (given as mean grey values), and tau (t) as a value inversely correlating with mobility are shown; ns = non
significant; p-values are shown within each graph.
doi:10.1371/journal.pone.0065149.g008
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In addition, we observed RAD21 degradation whenever there
was a shortage of one of the two SMC proteins. Thus, RAD21 is
quickly degraded, when it cannot be incorporated into the cohesin
complex. At least in SMC1-reduced cells, mRNA levels of Rad21
were increased, possibly in a vain attempt by the cell to
compensate for the loss of RAD21 protein. This loss is likely not
apoptosis-associated since firstly, the cells did not undergo
apoptosis as shown by several assays, and secondly, since the
65/64 kDa C-terminal fragment of RAD21 typically accumulat-
ing in apoptotic cells [42,43] was not observed in immuno blots
(data not shown), but would have been detected by the anti-
RAD21 antibody, which we used (which recognizes the region
between aa 575 to 631).
A further notable result of these studies is that less than 30% of
total cohesin is required to maintain proper cell cycle progression
and proliferation, and for an unaltered DNA damage response,
which includes DNA damage sensitivity, formation of cH2AX and
SMC6 foci, and apoptosis. Given the proportion of non-
transfected cells in our experiments, we estimate that 10 to 15%
of cohesin is sufficient for these important functions of cohesin.
This is consistent with previous estimates of a tightly chromosome-
associated pool of about one-third of all of cohesin [29]. Whether
SMC1 or SMC3 was scarce, the residual SMC1 or SMC3 protein
was found largely in the fraction of cohesin that is most tightly
associated with chromatin. This is supposedly the essential fraction
that provides a minimum of sister chromatid cohesion required for
chromosome segregation and cell proliferation. Thus, formation of
this pool is predominant at each cell cycle. Obviously, a cell that
would not form this pool would die, and thus in cultures suffering
from SMC1 or SMC3 deprivation, one selects for cells that
maintain this essential cohesin pool. However, since we did not
observe increased apoptosis or disturbances in cell division, we
assume that the essential cohesin pool is formed first from the
available cohesin molecules. One may speculate that a fraction of
cohesin may be quite stable, at least sufficiently stable for the few
days of treatment and analysis. This would imply that 10 to 15%
of cohesin is sufficient to support up to five cell divisions.
The differences in stability of SMC1 and SMC3, if left without a
partner, is striking and shall be further analyzed. In preparations
of SMC1/SMC3 dimers from calf thymus, we observed frequently
a 110–120 kDa polypeptide [44], which was identified as a
proteolytic fragment of the app. 160 kDa SMC1, but we never
observed an SMC3 degradation product. While highly speculative
at this point, one may entertain the idea of a biologically relevant
difference in proteolytic sensitivity, which would allow the cell to
remove SMC1 under certain, perhaps pathological, conditions.
The high evolutionary conservation of SMC1 and SMC3 within
mammals allowed us to establish a two-species system, in which
either bovine or mouse SMC1 or SMC3 replaces the respective
endogenous human SMC protein in fully functional manner. Also,
the EGFP tag placed onto the C-terminus of either bSMC1 or
msSMC3 did not visibly interfere with their functions. Rather, the
tagged proteins behaved as expected in terms of localization,
complex formation and mobility in FRAP assays. Such two-
species-systems lend themselves now to structure-function studies
of SMC proteins. Under conditions employed throughout these
experiments – with knock-down to about 25 or 30% of the
individual SMC protein and use of non-synchronized cells – we
avoided gross effects on cell cycle progression, cell viability, and
DNA repair, which under more forced conditions can be observed
in mammalian cells [40,41,45,46]. This allowed us to study the
behavior of endogenous or exogenous SMC proteins in vital cells.
The knock-down applied here was transient, for after about six
days, protein levels were back to starting levels.
Changes in SMC1 or SMC3 protein levels that may occur in
human pathologies possibly cause chromosome instability in
human colorectal cancers [34] or to chromosomal aberrations
[47,48]. Overexpression of SMC3 in fibroblasts may cause cell
transformation [49]. In several pathological human tissues
including colon carcinoma and liver metastatic cancer cells high
transcript levels of SMC3 were reported [49,50]. A gene dosage
effect of meiosis-specific cohesins REC8 and SMC1ß was recently
observed by us in oocytes and spermatocytes [51]. It is too early to
hypothesize about physiological functions of individual SMC1 or
SMC3 proteins, and the aberrant behavior seen in our experi-
ments would rather argue for pathological roles. For the related
SMC protein SMC5, which acts within the SMC5/SMC6
heterodimer in DNA repair, roles in mitotic progression and
maintenance of sister chromatid cohesion independent of dimer-
ization with SMC6 were proposed [52]. Mutations in SMC1 or
SMC3, which affect the stability of dimerization such as mutations
in their hinge domains, could alter the stability and localization of
the heterodimer partner. If the dimer dissociates more easily,
SMC1 may be degraded and SMC3 localized to the cytoplasm
with potential pathological consequences. Similarly, mutations
that increase DNA affinity of hinge dimers as described for certain
CdLS-type mutations, may reduce dissociation of cohesin from
chromatin [26].
The data presented here also call for caution in interpretation of
cohesin knock-down experiments. The reduction of either SMC1
or SMC3 triggers very different phenotypes with respect to their
cohesin partners. Depending on the particular phenotypes studied,
there can be significant consequences of massive cytoplasmic
SMC3 accumulation or of SMC1 degradation, for example. Thus,
one cannot simply derive firm conclusions on specific biological
effects just by depriving one of the cohesin subunits. Ideally, in
such experiments SMC1, SMC3 and RAD21 should be individ-
ually reduced in parallel and the specific phenotypes compared.
Similarly, overexpression of SMC1 or SMC3 without parallel
reduction of endogenous protein causes mis-behavior of the
protein. This is in agreement with earlier observations, where
over-expressed Smc3p in S. cerevisiae or over-expressed SMC1/
SMC3 in insect cells were seen in high amounts in cytosolic
fractions [10]. In mammalian cells, SMC1 or SMC3 overexpres-
sion also causes multipolar spindles [53]. SMC1 and SMC3 both
feature bipartite nuclear localization signals [54]. Yet, EGFP-
bSMC1 or EGFP-msSMC3 overexpressed in otherwise untreated
cells do not properly localize to the nucleus. Only if through
knock-down of endogenous SMC1 or SMC3 a more fitting
balance between total levels of SMC1 and SMC3 proteins is
approached, is nuclear localization achieved. Thus, the accurate
balance between SMC1 and SMC3 is essential for their proper
localization.
Supporting Information
Figure S1 Kinetics of SMC1 knock-down after transient
transfection 750 ng/mL esiSMC1 into 16106 HeLa cells
(A). Total RIPA cell extracts were analyzed by IB using anti-
SMC1 and anti-SMC3 antibodies and confirm the specific SMC1
reduction due to esiSMC1, starting at 24 h post transfection. The
percentages of SMC1 protein reduction compared to mock treated
cells and normalized to unaltered SMC3 protein levels are
indicated below. (B) Proliferation of cells harvested 72 h after
esiSMC1 treatment (as described in A) and analyzed by FACS
using CFSE staining. (C) The cell cycle status of cells treated as in
A) was measured by FACS using propidium iodine. Cells treated
with 0.1 mg/mL of mitomycine C (MMC) for 2 h and cultured for
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additional 24 h served as positive controls for cell cycle arrest.
Quantification of the values for G1, S and G2 phases are indicated
on the right. (D) IF staining of cells either mock-treated or treated
for 2 h with 0.1 mg/mL of mitomycine C (MMC) and cultured for
either 24 h or 48 h as indicated. Cells were also treated with
control esiRNA (esiEGFP) or esiSMC1 RNA, and stained for
SMC3, cH2AX and p957-SMC1. (E) IF staining for SMC6 of
cells treated for 72 h with control esiRNA (esiEGFP) or esiSMC1
and subsequently treated for 2 h with 0.1 mg/mL of mitomycine C
(MMC) and cultured for 48 h.
(TIFF)
Figure S2 Long term cell cycle studies (A) were
performed from cells collected 72 to 268 h after esiSMC1
or esiEGFP transfection (as described in S1A). As positive
control, MMC treated cells (1 mg/mL for 2 h and released for
24 h) are included. A second control used untreated cells mixed
with MMC treated (mix) cells in a 1:10 ratio to indicate small
changes in cell cycles. The values of G1, GS and G2 phases are
summarized in the graph below. (B) IB analysis of cells treated
with siSMC1 (50 pmol siSMC1/mL and 16106 cells) for 24 to
120 h compared to esiSMC1 and esiEGFP treated cells (72 h).
The membrane was probed with anti-SMC3, re-probed with anti-
SMC1, and then re-probed with anti-RAD21 antibodies. The
percentages of SMC1 and RAD21, normalized to levels of
karyopherin ß1, and compared to esiEGFP treated cells are
indicated at the bottom.
(TIFF)
Figure S3 Kinetics of SMC3 knock-down after siSMC3
treatment, analyzed by IB using anti-SMC3 antibody (A).
The membrane was successively reprobed with anti-SMC1, anti-
RAD21 and anti-karyopherin ß1 antibodies. The percentages of
protein levels that were normalized to karyopherin ß1 and
compared to esiEGFP cells are indicated below. (B) A represen-
tative cell cycle analysis is shown for cells collected 72 h after
esiRNA or siRNA treatment. (C) Quantification of the cell cycle
status of cells treated with esiRNA or siRNA (three independent
experiments).
(TIFF)
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